MDACC Study No:2013-0324 ( NCT No: NCT01928537)
Title:Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:RIGOSERTIB SODIUM (ON 01910.Na)
Study Status:Closed
Study Description:Patients with MDS often need blood cell transfusions to prevent diseases like
anemia (low red blood cell counts), bleeding, and/or serious infections.
However, these transfusions can lead to collections of abnormal cells, called
blasts, which can put you at a higher risk for developing leukemia.

The goal of this clinical research study is to learn if rigosertib can help to
control MDS in patients with an unusual number of blasts. The safety of this
drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:RIGOSERTIB SODIUM (ON 01910.Na)
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onconova Therapeutics Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults